Labcorp beats, ups 2026 outlook

 

Labcorp beats Q1 2026 estimates with EPS $4.25, raises 2026 outlook as Diagnostics and Central Labs drive double-digit EPS growth

• Q1 revenue grew 5.8% to $3.5B, with organic growth 3.1% and margins expanding.
• Adjusted EPS rose 10.6% to $4.25, supporting a full-year EPS guidance midpoint increase.
• Q1 2026 revenue was $3.54B (+6% YoY) as Labcorp beat overall Q1 2026 estimates.
• Diagnostics revenue grew 5%, driven by 2.5% volume growth and 2.6% price/mix improvement.
• Central Labs revenue grew 11% (5% organic constant currency), lifting BLS margins by 60 points.
• Management raised 2026 revenue and EPS midpoints, now guiding 5–6.1% revenue and $17.70–$18.35 EPS.
• Specialty testing in neurology and oncology and consumer OnDemand offerings are posting double-digit growth.
• LaunchPad efficiencies and AI initiatives are expected to further expand enterprise margins in 2026.
• BLS backlog is $8.6B with 12-month book-to-bill 1.04, underpinning multi-year visibility.
• Weather reduced Q1 revenue by ~$15M and organic Diagnostic volume by about 90 basis points.
• Main external risks are lab reimbursement changes from PAMA and CMS CRUSH, plus ACA volumes.
• Main concern: Policy and reimbursement uncertainty from PAMA, CMS CRUSH, and ACA exchange dynamics.
• Strong quarter, driven by broad-based organic growth in Diagnostics and Central Labs and margin expansion.

https://finviz.com/quote?t=LH&p=d